A.O. SMITH CORP (AOS.N 1.47%) (Market Cap of $10.4 billion USD)
makes residential and commercial water heating and water treatment equipment. The company distributes is products worldwide, mostly in North America, China and India.
A.O. Smith benefits from growth in the US construction industry, a move to more water efficient appliances and growth in the middle class in China and India who are buying water purification systems and water heaters for the first time. China is poised to become a $1 billion sales market for A.O. Smith in the next few years and India in the years thereafter, thanks to the introduction of a Goods & Sales Tax (GST) in an effort by the Indian government to modernize the economy and grow government revenue by increasing the reliability of tax collection. This should help boost domestic consumption.
Last purchase was on July 20th at $56.68 USD. I have owned the stock since 2013, my household owns it and the firm’s clients own it. We have no investment banking arrangements with the firm.
TOROMONT INDUSTRIES (TIH.TO 1.12%) (Market Cap of $4.5 billion CAD)
Sells, rents and services Caterpillar construction equipment and power systems in Ontario, Manitoba and the Maritimes. They also have a refrigeration subsidiary (CIMCO) that provides compression equipment to ice rinks in North America.
Toromont added to its Caterpillar network on August 28th with the $802 million purchase of Hewitt Group, providing it with new sales territories in Atlantic Canada. The deal should be earnings accretive and if Toromont management can accomplish a reduction in costs resulting in higher margins and profits, there should be more value in the shares.
Last purchase was on August 27th at $50.25. I have owned the stock since 1997, my household owns it and the firm’s clients own it. We have no investment banking arrangements with the firm.
NOVO NORDISK A/S (NVO.N) (Market Cap of $123 billion USD)
Is a pharmaceutical firm that focuses primarily on diabetes care. It has four new products out on the market that are proving to be better medicines than their competitors currently provide. Victoza is the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events (heart attacks). Semaglutide offers superior glucose control and weight loss in people with type 2 diabetes. Tresiba has a much longer half-life than Sanofi’s drug, Lantus, allowing it to be given at different times during the day, which comes in handy when people travel, are sick or forget to take it. Fiasp has received FDA approval to help Type 1 diabetes patients (juvenile diabetes) to moderate the rapid rise in blood sugar levels at meal time.
Last purchase was July 20th at $43.57 USD. I have owned the stock since 1995, my household owns it and the firm’s clients own it. We have no investment banking arrangements with the firm.
Disclosure Personal Family Portfolio
AOS Y Y Y
TIH Y Y Y
NVO Y Y Y